FDA Approves Vagal Nerve Stimulator for RA

Save

SetPoint Medical announced that the FDA has approved the company’s SetPoint System, a first-in-class neuroimmune modulation innovation for treatment of moderate-to-severe rheumatoid arthritis (RA) for those who are not adequately managed by—or cannot tolerate—existing advanced RA therapies, such as biological and targeted synthetic DMARDs.

Options for Refractory axSpA or PsA

Save

Although most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn't respond adequately to the interleukin-17 (IL-17) inhibitor ixekizumab (Taltz), enough did that it should still be considered in such cases, a Danish registry study indicated.

Rituximab is not Superior in EGPA

Save

A cohort study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) patients from the French Vasculitis Study Group failed to show superiority of rituximab compared to conventional strategy with glucocorticoids (GS) alone or in combination with cyclophosphamide.

Rheumatology Salaries Remain Low

Save

The annual Medscape Physician Compensation report was published and shows only modest salary gains for most specialists.

Top 20 Best Rheumatology Hospitals - 2025

Save

U.S. News & World Report has published its Best Hospitals for 2025, listing the best among many specialties, including rheumatology.  Each year, U.S. News ranks hospitals in 15 specialties and for the 8th year in a row, Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report.

HCQ Preserves Renal Function in Lupus Nephritis

Save

Lupus nephritis patients on long-term therapy with hydroxychloroquine showed significantly less decline in renal function, compared with patients treated otherwise, a 10-year retrospective study indicated.

Factors Affecting Biologic Use in Rheumatoid Arthritis

Save

A San Francisco Rheumatoid Arthritis Panel cohort survey between 1999–2011, showed numerous sociodemographic, disease, and health characteristics that influenced the initiation of treatment with biologic agents for rheumatoid arthritis (RA).

CKD & Osteoporosis Rx Revisited (7.25.2025)

Save

Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.

Osteoporosis Drug May Lower Osteoarthritis Risk

Save

A target trial emulation study using administrative claims suggests that romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis.

Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors

Save

Subclinical Synovitis Among Psoriasis Patients

Save

A systematic review shows that imaging can be used to detect subclinical synovitis among patients with psoriasis and may identify individuals at risk for future psoriatic arthritis.

Clinical Associations with Anti-RNA Polymerase III Antibodies

Save

A systematic review of anti-RNA polymerase III antibodies (ARA) in systemic sclerosis (SSc) patients finds ARA positivity in only 9% of SSc patients, but come with a higher risk of many potentially worrisome outcomes.